Clinical Trial: A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06793397) titled 'A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder' on Jan. 21.

Brief Summary: The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.

Study Start Date: July 08, 2025

Study Type: INTERVENTIONAL

Condition: Major Depressive Disorder (MDD)

Intervention: DRUG: CYB003

CYB003 is a synthetic psilocybin analog.

BEHAVIORAL: Psychological Support

Manualized psychological support performed by facilitator.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Cybin IRL Limited

Published by HT Digital Content Services wit...